Dr. Reddys Laboratories (RDY)
(Delayed Data from NYSE)
$71.49 USD
-0.66 (-0.91%)
Updated Apr 23, 2024 04:00 PM ET
After-Market: $71.52 +0.03 (0.04%) 7:58 PM ET
4-Sell of 5 4
C Value C Growth D Momentum C VGM
Income Statements
Fiscal Year end for Dr Reddy's Laboratories Ltd falls in the month of March .
All items in Millions except EPS data.
3/31/24 | 3/31/23 | 3/31/22 | 3/31/21 | 3/31/20 | |
---|---|---|---|---|---|
Sales | NA | 2,992 | 2,826 | 2,594 | 2,316 |
Cost Of Goods | NA | 1,296 | 1,325 | 1,185 | 1,069 |
Gross Profit | NA | 1,696 | 1,501 | 1,409 | 1,247 |
Selling & Adminstrative & Depr. & Amort Expenses | 0 | 1,001 | 1,112 | 960 | 812 |
Income After Depreciation & Amortization | 0 | 695 | 389 | 449 | 435 |
Non-Operating Income | NA | 57 | 50 | -74 | -182 |
Interest Expense | NA | 17 | 13 | 13 | 13 |
Pretax Income | NA | 734 | 426 | 361 | 239 |
Income Taxes | NA | 186 | 115 | 125 | -19 |
Minority Interest | NA | 0 | 0 | 0 | 0 |
Investment Gains/Losses | NA | 0 | 0 | 0 | 0 |
Other Income/Charges | NA | 0 | 0 | 0 | 0 |
Income From Cont. Operations | NA | 548 | 311 | 236 | 258 |
Extras & Discontinued Operations | NA | 0 | 0 | 0 | 0 |
Net Income (GAAP) | NA | 548 | 311 | 236 | 259 |
Depreciation Footnote | 3/31/24 | 3/31/23 | 3/31/22 | 3/31/21 | 3/31/20 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 0 | 849 | 545 | 624 | 600 |
Depreciation & Amortization (Cash Flow) | NA | 154 | 156 | 175 | 165 |
Income After Depreciation & Amortization | 0 | 695 | 389 | 449 | 435 |
Earnings Per Share Data | 3/31/24 | 3/31/23 | 3/31/22 | 3/31/21 | 3/31/20 |
---|---|---|---|---|---|
Average Shares | NA | 166.00 | 166.31 | 166.88 | 166.03 |
Diluted EPS Before Non-Recurring Items | NA | 3.30 | 2.35 | 2.01 | 2.79 |
Diluted Net EPS (GAAP) | NA | 3.30 | 1.87 | 1.52 | 1.56 |
Fiscal Year end for Dr Reddy's Laboratories Ltd falls in the month of March .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 865.78 | 828.14 | 821.00 | 717.85 |
Cost Of Goods | NA | 359.34 | 342.25 | 339.00 | 305.57 |
Gross Profit | NA | 506.44 | 485.89 | 482.00 | 412.28 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 299.23 | 270.83 | 267.00 | 273.25 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 207.21 | 215.06 | 215.00 | 139.03 |
Non-Operating Income | NA | 16.61 | 19.50 | 15.00 | 14.20 |
Interest Expense | NA | 4.73 | 4.25 | 5.00 | 4.04 |
Pretax Income | NA | 219.08 | 230.31 | 225.00 | 148.19 |
Income Taxes | NA | 53.62 | 52.17 | 54.00 | 41.44 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | 165.47 | 178.14 | 171.00 | 106.75 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | 165.47 | 178.14 | 171.00 | 106.75 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 167.68 | 166.37 | 166.53 | 167.14 |
Diluted EPS Before Non-Recurring Items | NA | 0.99 | 1.07 | 1.03 | 0.70 |
Diluted Net EPS (GAAP) | NA | 0.99 | 1.07 | 1.00 | 0.65 |